fbpx
Inform | Inspire | Initiate

Russia to partner with India for the mass production of its COVID-19 vaccine-SPUTNIK V

Russia is looking forward to a healthy partnership with India for the production of the claimed COVID vaccine, Sputnik V.

0

President Vladimir Putin had announced that his country has developed the world’s first vaccine against COVID-19, which forms a “stable immunity” against the disease. Russia after claiming the development of the world’s first COVID vaccine on Thursday said that it is looking forward to partner with India for the production of  COVID-19 vaccine, Sputnik V. An announcement to this effect was made by Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev on Thursday.

“The production of the vaccine is a very important issue. Currently, we are looking for a partnership with India. We believe that they are capable of producing the Gamaleya vaccine and it is very important to say that those partnerships to produce the vaccine will enable us to cover the demand that we have,” he said.

Dmitriev said Russia is looking forward to international cooperation.

Credit: Asianewsnet.com

“We are going to do clinical trials not just in Russia but also in the UAE, Saudi Arabia, probably in Brazil and India. We are planning to produce the vaccine in more than five countries and there is a very high demand from Asia, Latin America, Italy, and other parts of the world regarding the delivery of the vaccine,” he added.

Advertisements
Loading...

SputnikV has been developed by the Gamaleya Research Institute of Epidemiology and Microbiology, along with the RDIF. However, it has not been tested in Phase 3. The approach of the Gamaleya Institute with the vaccine, using two human adenoviruses serotypes: number 5 (Ad5) and number 26 (Ad26), has a clear advantage over the one-vector approach used by other developers,” said Alexander Gintsburg, the director of the Gamaleya Research Institute of Epidemiology and Microbiology and an academician at the Russian Academy of Sciences.

The Sputnik V vaccine consists of two shots that use different versions of adenoviruses — virus types, some of which cause the common cold — that the manufacturers have engineered to carry the gene for the surface protein of SARS-CoV-2 that causes COVID-19.

“The approach of the Gamaleya Institute with the vaccine, using two human adenoviruses serotypes: number 5 (Ad5) and number 26 (Ad26), has a clear advantage over the one-vector approach used by other developers,” Gintsburg added. 

 

Source: https://www.indiatoday.in/coronavirus-outbreak/video/exclusive-russia-keen-to-produce-covid-19-vaccine-in-india-says-kirill-dmitriev-1712695-2020-08-19

Advertisements
Loading...

[zombify_post]

Get real time updates directly on you device, subscribe now.

Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
You can unsubscribe at any time
Loading...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More